Holen Sie sich die Stockscreener-App
29.19
0.27%
-0.08
Handel nachbörslich:
29.19
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TGTX?
Forum
Prognose
Aktiensplit
Tg Therapeutics Inc Aktie (TGTX) Neueste Nachrichten
Is TG Therapeutics (TGTX) Pricing Reflecting Its Mixed Multi Year Share Performance? - Yahoo Finance
TGTX: Positive Phase 3 Analysis Results for Briumvi in Treating Multiple Sclerosis - GuruFocus
MS patients on BRIUMVI saw far fewer relapses and brain lesions - Stock Titan
Bank of America Securities bearish on TG Therapeutics (TGTX) post earnings - MSN
How Investors Are Reacting To TG Therapeutics (TGTX) Adding Azer-cel Milestone to Its MS Portfolio - Yahoo Finance
Azer Cel Milestone Broadens TG Therapeutics Autoimmune Pipeline And Valuation Story - Yahoo Finance
Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings - Finviz
Is TG Therapeutics Inc. (NKB2) stock included in top ETFs2026 Buyback Activity & AI Forecast Swing Trade Picks - Naître et grandir
TG Therapeutics (TGTX) sees price target drop from JPMorgan - MSN
TG Therapeutics to present BRIUMVI data at neurology meeting - Investing.com
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting - Bitget
What researchers will share on BRIUMVI in multiple sclerosis at AAN 2026 - Stock Titan
TG Therapeutics Azer Cel Milestone Adds Depth To Autoimmune Valuation Story - Sahm
Reports Suggest TG Therapeutics May Be Scaling Back Operations Amid Speculation on CafePharma Forum - geneonline.com
TG Therapeutics Q2 EPS Estimate Lowered by HC Wainwright - MarketBeat
TG Therapeutics Q4 EPS Forecast Lowered by HC Wainwright - MarketBeat
TG Therapeutics Confronts Rising AI Regulatory and IP Risks That Could Pressure Costs, Strategy, and Growth - The Globe and Mail
Precision BioSciences (DTIL) Hits Milestone, Secures $7.5M from TG Therapeutics - GuruFocus
TG Therapeutics, Inc. (TGTX) Growth Potential: Navigating A 47.65% Upside In Biotech - DirectorsTalk Interviews
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis - Business Wire
Is TG Therapeutics’ 2025 Earnings Miss and BRIUMVI Guidance Shift Altering The Investment Case For TGTX? - Sahm
HC Wainwright Raises Earnings Estimates for TG Therapeutics - MarketBeat
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2025 Earnings Call Transcript - Insider Monkey
TG Therapeutics (TGTX) Reports Financial Results for Q4 and Full Year 2025 - Finviz
TG Therapeutics (TGTX) Earnings Spark Debate As 72.6% Net Margin Defies Forecast Narratives - Sahm
TG Therapeutics Five Year Briumvi Data Highlights Durable Efficacy And Valuation Gap - Sahm
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line - The Globe and Mail
Decoding TG Therapeutics Inc (TGTX): A Strategic SWOT Insight - GuruFocus
TGTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TG Therapeutics Five Year BRIUMVI Data And What It Means For Valuation - Yahoo Finance
TG Therapeutics (NASDAQ:TGTX) Announces Quarterly Earnings Results, Misses Expectations By $0.21 EPS - MarketBeat
TG THERAPEUTICS, INC. SEC 10-K Report - TradingView
TG Therapeutics: "Strong Buy" On BRIUMVI's Massive Growth And Possible Expansion (TGTX) - Seeking Alpha
(TGTX) Movement as an Input in Quant Signal Sets - Stock Traders Daily
TG Therapeutics Experiences Evaluation Revision Amidst Evolving Market Dynamics - Markets Mojo
TG Therapeutics Q4 Earnings Call Highlights - MarketBeat
Q1 EPS Estimates for TG Therapeutics Raised by HC Wainwright - MarketBeat
TG Therapeutics: Q4 Earnings Snapshot - theheraldreview.com
TG Therapeutics (TGTX) Q4 2025 Earnings Transcript - The Globe and Mail
Earnings call transcript: TG Therapeutics Q4 2025 earnings miss EPS expectations - Investing.com
TG Therapeutics (TGTX) Misses Q4 Earnings Estimates - Yahoo! Finance Canada
TG Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
TG Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
TG Therapeutics: Fourth Quarter Financial Highlights - Bitget
TG THERAPEUTICS INC (NASDAQ:TGTX) Q4 2025 Earnings Miss Estimates Despite Strong BRIUMVI Outlook - ChartMill
TG Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
TG Therapeutics (TGTX) Reports Q4 Earnings Miss - GuruFocus
TG Therapeutics Q4 Earnings Fall, Revenue Rises; Issues 2026 Revenue Guidance; Shares Down Pre-bell - marketscreener.com
Earnings Flash (TGTX) TG Therapeutics Posts Q4 EPS $0.14, vs. FactSet Est of $0.35 - marketscreener.com
TGTX Projects Strong Financial Performance Through 2026 - GuruFocus
TGTX Financial Health and Future Funding Outlook - GuruFocus
TG THERAPEUTICS ($TGTX) Releases Q4 2025 Earnings - Quiver Quantitative
TG Therapeutics Q4 revenue rises on BRIUMVI sales, but profit dips - TradingView
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
TG Therapeutics Q4 Earnings Assessment - Benzinga
TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance - GlobeNewswire
TG Therapeutics, Inc. $TGTX Stock Holdings Increased by Citigroup Inc. - MarketBeat
TG Therapeutics (TGTX) Reports Q4 Revenue and Growth in BRIUMVI Adoption - GuruFocus
Does TG Therapeutics (TGTX) Offer Value After Recent Share Price Swings - simplywall.st
A Look at TG Therapeutics's Upcoming Earnings Report - Benzinga
TG Therapeutics faces earnings test as Briumvi growth accelerates By Investing.com - Investing.com Nigeria
1.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):